BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240625
DTEND;VALUE=DATE:20240628
DTSTAMP:20260515T200337
CREATED:20240223T112318Z
LAST-MODIFIED:20240223T112353Z
UID:38757-1719273600-1719532799@www.pharmajournalist.com
SUMMARY:Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Cell and gene therapies are revolutionizing healthcare\, offering promising solutions from curative treatments to long-term remission rates. As these treatments enter the market\, ensuring fair access while addressing coverage and payment complexities becomes paramount. \n  Introducing the inaugural Cell & Gene Therapy Pricing & Reimbursement Summit. Biotech\, pharma\, physicians\, healthcare providers\, and regulatory and government agencies will unite to address key issues such as the impact of regulatory acts\, implementing pricing models\, and collaborating on enhanced reimbursement strategies\, aiming to expedite the availability of these advanced therapies to patients. \nWith the recent approval of Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics\, and Lyfgenia by bluebird bio; significant strides in healthcare have been made\, offering groundbreaking treatments with transformative potential\, yet presenting substantial cost challenges. The Inflation Reduction Act and new Cell and Gene Therapy (CGT) Access Model aim to address these cost concerns by proposing innovative pricing models and reimbursement strategies to ensure affordability and widespread access to these life-changing therapies. \n Join us this June to discuss the impacts of this legislation and together\, we will optimize patient access and propel the success of commercial cell and gene therapy launches. \nSee the full agenda here: https://ter.li/d1rn7b
URL:http://www.pharmajournalist.com/event/cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240625
DTEND;VALUE=DATE:20240628
DTSTAMP:20260515T200337
CREATED:20240321T120048Z
LAST-MODIFIED:20240321T120048Z
UID:38913-1719273600-1719532799@www.pharmajournalist.com
SUMMARY:2nd mRNA Quality Control & Compliance Summit
DESCRIPTION:Regulatory guidelines and existing protocols to govern aspects of mRNA quality during development and manufacturing are still evolving\, creating a lack of clarity and consensus amongst the mRNA community. \nWithout a clear path forward\, drug developers risk comprising product quality\, safety and efficacy\, and so the 2nd mRNA Quality Control & Compliance Summit is back to Boston this June as the sole industry-centred forum dedicated to showcasing data and discussions on mRNA compliance and optimized documentation\, ensuring streamlined approval for mRNA therapeutics and vaccines! \nReuniting industry experts in quality control\, quality assurance\, analytical development\, and CMC\, this forum aims to navigate regulatory guidelines and identify tangible best practices towards optimized documentation\, discuss verification processes for platform methods and review method validation used to evaluate critical vaccine qualities\, all towards safeguarding faster mRNA drug approvals in line with regulatory expectations. \nDownload the free brochure or book your place now\, early birds are still available!
URL:http://www.pharmajournalist.com/event/2nd-mrna-quality-control-compliance-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR